Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
Six months after hematopoietic stem cell transplantation, nearly 20% of enrolled patients had experienced clinically significant PTSD symptoms.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
For patients with β-thalassemia who undergo HSCT, exposure to a normal microenvironment and the impairment of HSCs may be reversible in the presence of a normal microenvironment and in vivo protein restoration.
Unrelated donor selection should not be based on KIR in any of the evaluated settings, study results suggest.
Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.
Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.
While 85% of nonatopic donors matched with nonatopic recipients remained nonatopic, 61% of atopic donors matched with atopic recipients became nonatopic after AHCT.
